Skip to main content
. 2021 Mar;27(3):845–852. doi: 10.3201/eid2703.201087

Table 4. Demographic and clinical characteristics of extrapulmonary nontuberculous mycobacteria cases among hospitalized patients from 82 hospitals, United States, 2009–2014*.

Characteristics Extrapulmonary NTM, no. (%), n = 831 Disseminated, no. (%), n = 246 SST, no. (%), n = 298 Other, no. (%), n = 264 Both, no. (%), n = 23
Patient characteristic





Sex
F 409 (49) 98 (40) 164 (55) 133 (50) 14 (61)
M
422 (51)
148 (60)
134 (45)
131 (50)
9 (39)
Race/ethnicity
White 478 (58) 93 (38) 228 (77) 145 (55) 12 (52)
Black 269 (32) 138 (56) 38 (13) 83 (31) 10 (43)
Other
84 (10)
15 (6)
32 (11)
36 (14)
1 (4)
Age group, y
<18 91 (11) 13 (5) 43 (14) 35 (13) 0
>18–40 244 (29) 121 (49) 47 (16) 70 (27) 6 (26)
>40–60 266 (32) 86 (35) 93 (31) 78 (30) 9 (39)
>60
230 (28)
26 (11)
115 (39)
81 (31)
8 (35)
Ever had
Fungal Infection 92 (11) 53 (22) 13 (4) 22 (8) 4 (17)
HIV infection 104 (13) 63 (26) 9 (3) 26 (10) 6 (26)
Invasive cardiac procedure 18 (2) 4 (2) 6 (2) 7 (3) 1 (4)
Cancer 31 (4) 11 (4) 9 (3) 11 (4) 0
Other immunologic disorder†
18 (2)
8 (3)
3 (1)
7 (3)
0
In-hospital death or discharged to hospice
47 (6)
29 (12)
5 (2)
12 (5)
1 (4)
Hospital characteristic
Region
South 375 (45) 147 (60) 94 (32) 125 (47) 9 (39)
Northeast 202 (24) 44 (18) 95 (32) 56 (21) 7 (30)
Midwest 200 (24) 44 (18) 88 (30) 64 (24) 4 (17)
West 54 (6) 11 (4) 21 (7) 19 (7) 3 (13)
Setting
Urban 764 (92) 231 (94) 278 (93) 234 (89) 21 (91)
Rural 67 (8) 15 (6) 20 (7) 30 (11) 2 (9)
Teaching status‡
Teaching facility 686 (83) 210(85) 247 (83) 209 (79) 20 (87)
Not teaching facility 112 (13) 30 (12) 35 (12) 209 (17) 3 (13)

*Data from in Cerner Health Facts database (https://sc-ctsi.org/resources/cerner-health-facts). Both, disseminated and SST infection; SST, skin and soft tissue. 
†Antineoplastic and immunosuppressive drugs causing adverse effects in therapeutic use, autoimmune disease, not elsewhere classified, common variable immunodeficiency, encounter for antineoplastic immunotherapy, immunodeficiency with predominant T-cell defect, unspecified, other and unspecified nonspecific immunological findings, other specified disorders involving the immune mechanism, personal history of immunosuppression therapy, unspecified disorder of immune mechanism, unspecified immunity deficiency.
‡Status unknown for 33 patients.